Cocrystal Pharma Future Growth
Future criteria checks 0/6
Cocrystal Pharma's earnings are forecast to decline at 15.1% per annum. EPS is expected to decline by 14.4% per annum.
Key information
-15.1%
Earnings growth rate
-14.4%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -26 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -23 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -20 | N/A | N/A | 3 |
| 9/30/2024 | N/A | -19 | N/A | N/A | N/A |
| 6/30/2024 | N/A | -18 | -14 | -14 | N/A |
| 3/31/2024 | N/A | -17 | -16 | -16 | N/A |
| 12/31/2023 | N/A | -18 | -15 | -15 | N/A |
| 9/30/2023 | N/A | -18 | -16 | -16 | N/A |
| 6/30/2023 | N/A | -20 | -23 | -22 | N/A |
| 3/31/2023 | N/A | -40 | -21 | -21 | N/A |
| 12/31/2022 | N/A | -39 | -22 | -21 | N/A |
| 9/30/2022 | N/A | -38 | -20 | -19 | N/A |
| 6/30/2022 | N/A | -36 | -16 | -16 | N/A |
| 3/31/2022 | N/A | -16 | -15 | -15 | N/A |
| 12/31/2021 | N/A | -14 | -13 | -13 | N/A |
| 9/30/2021 | 1 | -12 | -12 | -12 | N/A |
| 6/30/2021 | 1 | -11 | -10 | -10 | N/A |
| 3/31/2021 | 2 | -10 | -10 | -9 | N/A |
| 12/31/2020 | 2 | -10 | -10 | -10 | N/A |
| 9/30/2020 | 2 | -56 | -9 | -9 | N/A |
| 6/30/2020 | 2 | -55 | -7 | -7 | N/A |
| 3/31/2020 | 2 | -53 | -6 | -6 | N/A |
| 12/31/2019 | 7 | -48 | -2 | -2 | N/A |
| 9/30/2019 | 6 | -45 | -2 | -2 | N/A |
| 6/30/2019 | 6 | -45 | -3 | -3 | N/A |
| 3/31/2019 | 5 | -45 | -4 | -4 | N/A |
| 12/31/2018 | N/A | -49 | -8 | -8 | N/A |
| 9/30/2018 | N/A | 0 | -8 | -8 | N/A |
| 6/30/2018 | N/A | 0 | N/A | -8 | N/A |
| 3/31/2018 | N/A | 0 | N/A | -7 | N/A |
| 12/31/2017 | N/A | -1 | N/A | -7 | N/A |
| 9/30/2017 | N/A | -72 | N/A | -8 | N/A |
| 6/30/2017 | N/A | -71 | N/A | -9 | N/A |
| 3/31/2017 | N/A | -73 | N/A | -13 | N/A |
| 12/31/2016 | N/A | -75 | N/A | -15 | N/A |
| 9/30/2016 | N/A | -40 | N/A | -15 | N/A |
| 6/30/2016 | 0 | -38 | N/A | -15 | N/A |
| 3/31/2016 | 0 | -38 | N/A | -13 | N/A |
| 12/31/2015 | 0 | -50 | N/A | -10 | N/A |
| 9/30/2015 | 0 | -22 | N/A | -9 | N/A |
| 6/30/2015 | 0 | -24 | N/A | -7 | N/A |
| 3/31/2015 | 0 | -16 | N/A | -6 | N/A |
| 12/31/2014 | 0 | 0 | N/A | -6 | N/A |
| 9/30/2014 | N/A | 1 | N/A | -5 | N/A |
| 6/30/2014 | N/A | 3 | N/A | -5 | N/A |
| 3/31/2014 | N/A | -3 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8CC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 8CC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 8CC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 8CC's revenue is forecast to grow faster than the German market.
High Growth Revenue: 8CC is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 8CC's Return on Equity is forecast to be high in 3 years time